Form 4: Pacific Biosciences Director Kathy Ordonez Granted 65,000 Stock Options

Pacific Biosciences of California, Inc. director Kathy Ordonez was granted 65,000 stock options with an exercise price of $1.03, vesting monthly over one year.

Summary

• Kathy Ordonez, a Director of Pacific Biosciences of California, Inc. (PACB), was granted 65,000 stock options.
• The transaction date for this grant was June 4, 2025.
• Each option has an exercise price of $1.03.
• The options begin vesting on July 4, 2025, and will vest monthly over a one-year period.
• The options are set to expire on June 4, 2035.
• Vesting is contingent on Ms. Ordonez's continued service as a director through the applicable vesting dates.
• Following this transaction, Ms. Ordonez beneficially owns 65,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a Form 4 is primarily a factual disclosure, the grant of options to a director is a positive signal of continued alignment and incentivization, though it doesn't reflect operational performance.

Positives

• The grant of stock options aligns the director's interests with long-term shareholder value.
• The vesting schedule encourages continued service and commitment from the director to the company's success.

Future Outlook

NA

Industry Context

This is a routine insider transaction disclosure for a director's equity compensation, common across publicly traded companies, particularly in the biotechnology and life sciences sector like Pacific Biosciences, to align executive and director incentives with company performance.

Comparison to Industry Standards

• The grant of stock options to directors is a standard practice in corporate governance, particularly within the biotechnology and life sciences industries, to incentivize long-term commitment and align interests with shareholders.
• The vesting schedule over one year is also a common approach for director equity awards, similar to practices seen at companies like Illumina (ILMN) or Twist Bioscience (TWST), which often use equity grants as a significant component of non-employee director compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align their interests with long-term shareholder value, potentially leading to better governance and strategic decisions that benefit the company's stock performance.

Next Steps

• The stock options will continue to vest monthly over the next year, contingent on Kathy Ordonez's continued service as a director.

Key Dates

Keywords

Pacific Biosciences, PACB, Stock Option Grant, Form 4, Insider Transaction, Director Compensation, Equity Compensation, Kathy Ordonez, SEC Filing